Lupin gets tentative approval from USFDA for Calcium, Magnesium, Potassium, and Sodium Oxybates Oral Solution
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Lupin is exclusive first-to-file and may be eligible to receive a 180-day exclusivity period at product launch
Astellas stands on the forefront of healthcare change to turn innovative science into value for patients
The NDA filing for deuruxolitinib with the U.S. FDA is based on two pivotal Phase III trials
Sugammadex Injection is indicated for the reversal of neuromuscular blockade induced by rocuronium bromide and vecuronium bromide
Tolvaptan Tablets (RLD Jynarque) had estimated annual sales of USD 287 million in the U.S. (IQVIA MAT August 2023)
NRT offers 50% higher success rate in quitting smoking compared to unassisted attempts
Advances Amgen's mission to serve patients with rare disease medicines
This integrated care offering is a step forward in our vision of providing an effective continuum of care for patients
The product is an additional formulation of Cresemba Capsule 100 mg and Cresemba Intravenous Infusion 200 mg
Subscribe To Our Newsletter & Stay Updated